1461096338-463e9263-1394-4b08-ba2d-e73251cf30d2

1. A pharmaceutical composition for the treatment andor prevention of chlamydial infections, characterised in that the composition comprises a plant-derived phenolic compound or an extract or a fraction or a partial fraction containing it, or a corresponding synthetic compound or a synthetic derivative thereof, or a mixture of said compounds, optionally as a mixture with a sulphur compound originating from garlic.
2. A composition according to claim 1, characterised in that an anti-chlamydial effect of the plant-derived phenolic compound or an extract or a fraction or a partial fraction containing it, or of a corresponding synthetic compound or a synthetic derivative thereof is equal or more than 30% and preferably the anti-chlamydial effect is equal or more than 90%, as inhition of formation of inclusions as defined in the examples.
3. A composition according to claim 1 or 2, characterised in that the plant-derived phenolic compound is a phenolic compound formed from shikimic acid via a biosynthetic pathway, a phenolic compound formed through the biochemical acetate-malonate pathway or a phenolic compound formed as a result of combinations of both pathways, or an extract or a fraction or a partial fraction containing it or a fraction containing simple phenols, flavonoids, their derivatives, polyphenols, diterpene phenols and diterpene kinones, or a fraction after the tannin and diterpene fractions have been removed from the fraction.
4. A composition according to any one of claims 1-3, characterised in that the plant-derived phenolic compound is a flavone, a flavonol, a flavonone, a isoflavanoid, a phenylmethane-derived compound or a phenylpropane-derived compound, and the corresponding synthetic compound or derivative thereof is a synthetic flavonoid or a synthetic coumarin.
5. A composition according to any one of claims 1-4, characterised in that the extract or fraction or partial fraction is a natural plant extract or a dietary plant extract.
6. A composition according to any one of claims 1-5, characterised in that the extract or fraction or partial fraction is an extract of: Mentha longifolia, Mentha arvensis, Galeopsis speciosa, Salvia officinalis, Thymus vulgaris, Rumex acetocella, Rosa rugosa, Veronica longifolia, Symphytum asperum, Artemisia vulgaris, Convallaria majalis, Quercus robur; Daucus carota, Fragaria iinumae, Brassica oleracea, Brassica napus, Medicago sativa, Citrus sinensis, Phloem flour or Vaccinum myrtillus.
7. A composition according to any one of claims 1-6, characterised in that the composition comprises a plant-derived phenolic compound selected from apigenin, luteolin, flavone, quercetin, rhamnetin, morin, genistein, methyl gallate, propyl gallate, octyl gallate, dodecyl gallate, isopropyl gallate, umbelliferone, scopoletin, methoxy psoralen, xanthotoxin, coumarin, ()-epigallocatechin, ()-epicatechin, ()-catechin and ()-epicatechin gallate, or a corresponding synthetic compound or a derivative thereof selected from coumarin 106, 2-methoxy–naphtoflavone, 6,2-dimethoxyflavone, 6-methylcoumarin, alpha-naphtoflavone, rotanone and 7-diethyl-amino-3-thenoylcoumarin.
8. A composition according to any one of claims 1-7, characterised in that the composition comprises quercetin, morin, rhamnetin, octylgallate when the cause of the infection is C. pneumoniae and quercetin, morin, rhamnetin or when the cause of the infection is C. trachomatis.
9. A composition according to any one of claims 1-8, characterised in that the composition contains 25 g to 3000 mg, calculated as an aglycon, of the a plant-derived phenolic compound or an extract or a fraction or a partial fraction containing it, or a corresponding synthetic compound or a synthetic derivative thereof in the aglycon or glycosidic form.
10. A pro-health composition, characterised in that the composition comprises a plant-derived phenolic compound or an extract or a fraction or a partial fraction containing it, or a corresponding synthetic compound or a synthetic derivative thereof, or a mixture of said compounds, optionally as a mixture with a sulphur compound originating from garlic.
11. A pro-health composition according to claim 10, characterised in that an anti-chlamydial effect of the plant-derived phenolic compound or an extract or a fraction or a partial fraction containing it, or of a corresponding synthetic compound or a synthetic derivative thereof is equal or more than 30% and preferably the anti-chlamydial effect is equal or more than 90%, as inhition of formation of inclusions as defined in the examples.
12. A pro-health composition according to claim 10 or 11, characterised in that the plant-derived phenolic compound is a phenolic compound formed from shikimic acid via a biosynthetic pathway, a phenolic compound formed through the biochemical acetate-malonate pathway or a phenolic compound formed as a result of combinations of both pathways, or an extract or a fraction or a partial fraction containing it or a fraction containing simple phenols, flavonoids, their derivatives, polyphenols, diterpene phenols and diterpene kinones, or a fraction after the tannin and diterpene fractions have been removed from the fraction.
13. A pro-health composition according to any one of claims 10-12, characterised in that the plant-derived phenolic compound is a flavone, a flavonol, a flavonone, a isoflavanoid, a phenylmethane-derived compound or a phenylpropane-derived compound, and the corresponding synthetic compound or derivative thereof is a synthetic flavonoid or a synthetic coumarin.
14. A pro-health composition according to any one of claims 10-13, characterised in that the extract or fraction or partial fraction is a natural plant extract or a dietary plant extract.
15. A pro-health composition according to any one of claims 10-14, characterised in that the extract or fraction or partial fraction is an extract of: Mentha longifolia, Mentha arvensis, Galeopsis speciosa, Salvia officinalis, Thymus vulgaris, Rumex acetocella, Rosa rugosa, Veronica longifolia, Symphytum asperum, Artemisia vulgaris, Convallaria majalis, Quercus robur, Daucus carota, Fragaria iinumae, Brassica oleracea, Brassica napus, Medicago sativa, Citrus sinensis, Phloem flour or Vaccinum myrtillus.
16. A pro-health composition according to any one of claims 10-15, characterised in that the composition comprises a plant-derived phenolic compound selected from apigenin, luteolin, flavone, quercetin, rhamnetin, morin, genistein, methyl gallate, propyl gallate, octyl gallate, dodecyl gallate, isopropyl gallate, umbelliferone, scopoletin, methoxy psoralen, xanthotoxin, coumarin, ()-epigallocatechin, ()-epicatechin, ()-catechin and ()-epicatechin gallate, or a corresponding synthetic compound or a derivative thereof selected from coumarin 106, 2-methoxy-a-naphtoflavone, 6,2-dimethoxyflavone, 6-methylcoumarin, alpha-naphtoflavone, rotanone and 7-diethyl-amino-3-thenoylcoumarin.
17. A pro-health composition according to any one of claims 10-16, characterised in that the composition comprises quercetin, morin, rhamnetin, octylgallate when the cause of the infection is C. pneumoniae and quercetin, morin, rhamnetin or when the cause of the infection is C. trachomatis.
18. Use of a pro-health composition according to any claim 10-17 in the preparation of food stuffs or as such to be added to the daily nourishment.
19. Use of a plant-derived phenolic compound or an extract or a fraction or a partial fraction containing it, or a corresponding synthetic compound or a synthetic derivative thereof, or a mixture of said compounds, optionally as a mixture with a sulphur compound originating from garlic in the manufacture of a medicament for the treatment andor prevention of chlamydial infections.
20. Use according to claim 19, characterised in that an anti-chlamydial effect of the plant-derived phenolic compound or an extract or a fraction or a partial fraction containing it, or of a corresponding synthetic compound or a synthetic derivative thereof is equal or more than 30% and preferably the anti-chlamydial effect is equal or more than 90%, as inhition of formation of inclusions as defined in the examples.
21. Use according to claim 19 or 20, characterised in that the plant-derived phenolic compound is a phenolic compound formed from shikimic acid via a biosynthetic pathway, a phenolic compound formed through the biochemical acetate-malonate pathway or a phenolic compound formed as a result of combinations of both pathways, or an extract or a fraction or a partial fraction containing it or a fraction containing simple phenols, flavonoids, their derivatives, polyphenols, diterpene phenols and diterpene kinones, or a fraction after the tannin and diterpene fractions have been removed from the fraction.
22. Use according to any one of claim 19-21, characterised in that the plant-derived phenolic compound is a flavone, a flavonol, a flavonone, a isoflavanoid, a phenylmethane-derived compound or a phenylpropane-derived compound, and the synthetic compound or derivative is a synthetic flavonoid or a coumarin.
23. Use according to any one of claims 19-22, characterised in that the extract or fraction or partial fraction is a natural plant extract or a dietary plant extract.
24. Use according to any one of claims 19-23, characterised in that the extract or fraction or partial fraction is an extract of: Mentha longifolia, Mentha arvensis, Galeopsis speciosa, Salvia officinalis, Thymus vulgaris, Rumex acetocella, Rosa rugosa, Veronica longifolia, Symphytum asperum, Artemisia vulgaris, Convallaria majalis, Quercus robur, Daucus carota, Fragaria iinumae, Brassica oleracea, Brassica napus, Medicago sativa, Citrus sinensis, Phloem flour or Vaccinum myrtillus.
25. Use according to any one of claims 19-24, characterised in that the plant-derived phenolic compound is selected from apigenin, luteolin, flavone, quercetin, rhamnetin, morin, genistein, methyl gallate, propyl gallate, octyl gallate, dodecyl gallate, isopropyl gallate, umbelliferone, scopoletin, methoxy psoralen, xantho-toxin, coumarin, ()-epigallocatechin, ()-epicatechin, ()-catechin and ()-epicatechin gallate and the corresponding synthetic compound or a derivative thereof is selected from coumarin 106, 2-methoxy-a-naphtoflavone, 6,2-dimethoxyflavone, 6-methylcoumarin, alpha-naphtoflavone, rotanone and 7-diethyl-amino-3-thenoylcoumarin.
26. Use according to any one of claims 19-25, characterised in that quercetin, morin, rhamnetin or octylgallate is used when the cause of the infection is C. pneumoniae and quercetin, morin or rhamnetin is used when the cause of the infection is C. trachomatis.
27. Use according to any one of claims 19-26, characterised in that 25 g to 3000 mg, calculated as an aglycon, of the a plant-derived phenolic compound or an extract or a fraction or a partial fraction containing it, or a corresponding synthetic compound or a synthetic derivative thereof is used in the aglycon or glycosidic form.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. An alignment system comprising:
a tunable narrow pass-band filter configured to:
receive broad-band radiation, and
filter the broad-band radiation into narrow-band radiation;

a relay and mechanical interface configured to:
receive the narrow-band radiation, and
adjust a profile of the narrow-band radiation based on a physical property of a plurality of alignment targets on a substrate; and

a focusing system configured to focus the adjusted narrow-band radiation on the plurality of alignment targets.
2. The alignment system of claim 1, wherein the tunable narrow pass-band filter is configured to filter the broad-band radiation into narrow-band linearly polarized radiation.
3. The alignment system of claim 1, wherein the tunable narrow pass-band filter is further configured to select a plurality of narrow-band wavelength set points at a same time or nearly the same time.
4. The alignment system of claim 1, wherein the tunable narrow pass-band filter is further configured to modulate intensity and wavelength of the broad-band radiation.
5. The alignment system of claim 1, wherein the tunable narrow pass-band filter is further configured to provide a plurality of pass-band filters at a same time or nearly the same time.
6. The alignment system of claim 1, wherein the tunable narrow pass-band filter is an Acousto-Optical Tunable Filter (AOTF).
7. The alignment system of claim 1, wherein the narrow-band radiation has a mean wavelength of approximately 980 nm.
8. The alignment system of claim 1, wherein the broad-band radiation ranges from 450 nm to 2500 nm.
9. A method to align a substrate in a lithographic apparatus, the method comprising:
filtering, using a tunable narrow pass-band filter, a broad-band radiation to generate a narrow-band polarized radiation;
receiving, using a relay and mechanical interface, the narrow-band polarized radiation from the tunable narrow pass-band filter;
adjusting a profile of the narrow-band polarized radiation; and
focusing the adjusted narrow-band polarized radiation on an alignment target on the substrate.
10. The method of claim 9, further comprising:
selecting, using the tunable narrow pass-band filter, a plurality of narrow-band wavelength set points at a same time or nearly the same time.
11. The method of claim 9, further comprising:
modulating, using the tunable narrow pass-band filter, intensity and wavelength of the broad-band radiation.
12. The method of claim 9, further comprising:
providing, using the tunable narrow pass-band filter, a plurality of pass-band filters at a same time or nearly the same time.
13. The method of claim 9, wherein the tunable narrow pass-band filter is an Acousto-Optical Tunable Filter (AOTF).
14. A lithographic apparatus comprising:
a tunable narrow pass-band filter configured to:
receive a broad-band radiation, and
filter the broad-band radiation into narrow-band radiation;

a relay and mechanical interface configured to:
receive the narrow-band radiation, and
adjust a profile of the narrow-band radiation based on physical properties of alignment targets on a substrate; and

a focusing system configured to focus the adjusted narrow-band radiation on the plurality of alignment targets.
15. The lithographic apparatus of claim 14, wherein the tunable narrow pass-band filter is configured to filter the broad-band radiation into narrow-band linearly polarized radiation.
16. The lithographic apparatus of claim 14, wherein the tunable narrow pass-band filter is further configured to select a plurality of narrow-band wavelength set points at a same time or nearly the same time.
17. The lithographic apparatus of claim 14, wherein the tunable narrow pass-band filter is further configured to modulate intensity and wavelength of the broad-band radiation.
18. The lithographic apparatus of claim 14, wherein the tunable narrow pass-band filter is further configured to provide a plurality of pass-band filters at a same time or nearly the same time.
19. The lithographic apparatus of claim 14, wherein the tunable narrow pass-band filter is an Acousto-Optical Tunable Filter (AOTF).
20. The lithographic apparatus of claim 14, wherein the tunable narrow pass-band filter comprises a library of spectral filters.